KLI
ABBV icon

Kelman-Lazarov Inc’s AbbVie ABBV Stock Holding History

Kelman-Lazarov Inc’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,238
Closed -$283K – 141
2025
Q4 		$283K Buy
+1,238
New +$282K 0.04% 119
2017
Q1 		– Sell
-399
Closed -$25K – 103
2016
Q4 		$25K Hold
399
– – 0.01% 209
2016
Q3 		$25.1K Hold
399
– – 0.01% 234
2016
Q2 		$25K Buy
+399
New +$24.3K 0.01% 221

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Kelman-Lazarov Inc's ABBV Position: Q1 2026 in Review

Kelman-Lazarov Inc sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 1,238 shares — an estimated $283K sold.

Kelman-Lazarov Inc first reported a position in ABBV in Q2 2016 and held it in 4 quarters. The position peaked at $283K in Q4 2025. 4,097 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Kelman-Lazarov Inc reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • Kelman-Lazarov Inc sold 1,238 AbbVie shares in Q1 2026, an estimated $283K.
  • Kelman-Lazarov Inc first reported a position in AbbVie in Q2 2016 and held it in 4 quarters.
  • Kelman-Lazarov Inc's AbbVie position peaked at $283K in Q4 2025.
  • 4,097 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Kelman-Lazarov Inc's 13F filing for Q1 2026, filed 27 Apr 2026.